Company Overview and News

 
UPDATE 2-NZ's Goodman Property Trust sells VXV portfolio to Blackstone funds

2018-05-17 reuters
* Deal comes after rumoured Blackstone purchase of HNA Group’s Sydney building (Adds background on Blackstone Group’s recent activity)

1
Deals of the day-Mergers and acquisitions

2018-04-13 reuters
April 13 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Friday:

 
Hopkins in $508m panel beating buyout

2018-04-13 businessnews.com.au
Perth-based Andrew Hopkins has led a $508 million buyout of national panel beating business AMA Group, with the deal backed by private equity giant Blackstone.

 
AMA Group to demerge automotive component, accessory and procurement business

2018-04-13 proactiveinvestors.com.au
AMA Group Ltd (ASX:AMA) intends to demerge its automotive component, accessory and procurement (ACAD) business and enter a $508 million transaction for its remaining vehicle panel repair business.

 
Australia's AMA Group to sell vehicle panel repair business to Blackstone for $394.9 mln

2018-04-13 reuters
(Reuters) - AMA Group (AMA.AX) said on Friday it would demerge its automotive component, accessory and procurement business and separately sell its vehicle panel repair business to funds advised by buyout firm Blackstone Group (BX.N) for an enterprise value of A$508 million ($394.92 million).

 
Asian shares gain after Wall Street#39;s record highs; Kospi rises 1.1%

2018-01-29 moneycontrol
Asian shares traded higher early on Monday following significant gains stateside in the last session, which saw major US indexes touch record highs.

 
Automotive Solutions Group tops the ASX % Gainers following takeover offer

2017-11-02 proactiveinvestors.com.au
Automotive Solutions Group Ltd (ASX:4WD) shares have soared 55% to $0.34 intra-day following a takeover offer from AMA Group Ltd (ASX:AMA).

 
Crash repair: How Ray Malone became head of ASX-listed company AMA Group

2017-08-11 smh.com.au
He owned some panel shops but saw the consolidation within the crash repair industry and decided to get on the front foot.

 
Earnings season may challenge Trump reflation trade

2017-02-12 theage.com.au
Despite the overarching global narrative of a return to growth and inflation, this reporting season may show that life among many listed Australian businesses remains a slog.

 
Earnings season may challenge Trump reflation trade

2017-02-12 smh.com.au
Despite the overarching global narrative of a return to growth and inflation, this reporting season may show that life among many listed Australian businesses remains a slog.

 
Appendix 3B & 708A notice

2016-04-27 asx.com.au

 
 
Half Yearly Report and Accounts

2016-02-26 asx.com.au

 
AMA Delivers Strong Growth

2016-02-26 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...